指南与共识泌尿男性生殖肿瘤

膀胱癌的定义、终点与临床试验设计:癌症免疫治疗学会与国际膀胱癌组织的推荐

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
指南 / 共识 · J Clin Oncol · 2023-10-04

癌症免疫治疗学会(SITC)与国际膀胱癌组织(IBCG)召集多学科国际共识专家组,针对低危和中危非肌层浸润性膀胱癌、高危非肌层浸润性膀胱癌、肌层浸润性膀胱癌的新辅助和辅助治疗以及转移性尿路上皮癌,制定疾病状态定义、终点、试验设计、评估、样本量计算和病理学考量的推荐,以促进研究统一性和药物开发。

要点

  • 共识专家组针对不同分期膀胱癌制定临床试验设计推荐。
  • 推荐覆盖疾病状态定义、终点、试验设计、评估、样本量计算和病理学考量。
  • 推荐旨在促进研究统一性并促进该疾病药物开发。

核心结论

  • SITC-IBCG膀胱癌临床试验设计共识专家组制定的推荐将促进研究统一性并促进该疾病药物开发。

研究设计与样本

  • SITC与IBCG召集多学科国际共识专家组,通过小组和全体会议公开交流与科学辩论、问卷调查及临床问卷回复制定推荐。
  • 专家组在2021年膀胱癌倡导网络(BCAN)智库虚拟公开会议上通过报告和公开讨论征求对推荐的意见。

主要发现

  • 共识专家组针对低危和中危非肌层浸润性膀胱癌、高危非肌层浸润性膀胱癌、肌层浸润性膀胱癌的新辅助和辅助治疗以及转移性尿路上皮癌制定了分期特异性膀胱癌临床试验设计推荐。
  • 推荐涵盖疾病状态的最佳定义、终点、试验设计、评估、样本量计算和病理学考量。

关键数值与推荐

  • 推荐内容总结于随文表格中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel. METHODS: Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually). RESULTS: The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text. CONCLUSION: These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kamat AM, Apolo AB, Babjuk M, et al. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023. PMID: 37793077. doi:10.1200/JCO.23.00307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。